fda semaglutide warning news october 2025 Patient Safety Updates Recently Approved Wegovy Pill Expands

doi:10.1111/cen.14399

Muscogiuri G, DeFronzo RA, Gastaldelli A, Holst JJ

Why Effects Extend Beyond Blood Sugar The broad benefits of GLP-1 medications stem from addressing underlying metabolic dysfunction rather than just treating elevated glucose: Weight loss addresses root causes: Excess weight drives insulin resistance, the core problem in Type 2 diabetes

Several drugs evaluated in the field of cardiovascular prevention have shown to simultaneously have an anti-inflammatory (CRP lowering) and cardioprotective effect (decrease in cardiovascular atherosclerotic events)

Importantly, a WM-CR group for RETA could not be established because of the extreme weight loss observed with RETA which could not be implemented through CR alone

As next steps, we need larger and longer studies involving more diverse groups of patients